#Incyte

[newshare24]

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz ®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

” Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS) and all secondary endpoints in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) ” Data presented at the European Society for Medical (TASE:) Oncology (ESMO) Asia Congress 2024 support the planned 2025 filing of a supplemental Biologics License Application (sBLA) in the U.S. for retifanlimab in…

[pier-carlo-universe]

La Vitiligine Week arriva in Piemonte: incontri gratuiti con dermatologi per sensibilizzare e supportare i pazienti

Dal 25 al 30 novembre, Torino e Novara saranno tra le città protagoniste della Vitiligine Week, una campagna nazionale dedicata a chi convive con questa malattia cronica autoimmune.

Dal 25 al 30 novembre, Torino e Novara saranno tra le città protagoniste della Vitiligine Week, una campagna nazionale dedicata a chi convive con questa malattia cronica autoimmune. L’iniziativa, promossa da SIDeMaST e APIAFCO, offrirà incontri gratuiti con specialisti in dermatologia per migliorare la consapevolezza sulla vitiligine e presentare le ultime possibilità terapeutiche. Un’occasione…

[cleverthylacine]

I've been mainlining Westworld.

I love Dolores. I really do.

She's done horrible things but G-d forbid women do anything.

Also she would be such a fabulous Decepticon.

[dailyanarchistposts]

Biotechnology and the future of humanity

Animals Are Commodities Too

Under slavery human individuals are owned, are property. Under capitalism workers aren’t owned but they have to sell their labour/time/creativity because capitalists own everything (land, the means of production, transport and communication etc) that would enable people to live outside of wage labour and the market place. Now, instead of individuals owning non-human animals as part of their subsistence, corporations are claiming the right to ‘own’ whole species of animals. This process of patenting life can be traced back to the 1980 US Supreme Court ruling, which stated that a GM bacterium (modified to digest oil) could be patented. Not just that one bacterium of course but the whole, created species. In 1985 the US Patent and Trademark Office ruled that GM plants, seeds and plant tissues could be patented. Now the corporations can demand royalties and licence payments every time farmers use those plants or seeds. Monsanto holds a patent on (i.e. owns and rents out) all GM cotton and soya. Patents have been granted on biological characteristics of plants as well. For example, a patent has been issued to Sungene for a variety of sunflower that has a high oleic acid content. But the patent covers the characteristic as well as the genes that code for it, so any plant breeder who achieves the same result by traditional methods could be sued.

In 1987 animals joined the biotech market place when a Harvard biologist patented ‘oncomouse’, a GM organism (mouse) predisposed to develop cancer for use in medical ‘research’. By 1997 40 GM ‘species’ of animal had been patented, including turkey, nematodes, mice and rabbits. Hundreds of other patents are pending on pigs, cows, fish, sheep and monkeys among others. In 1976 a leukaemia patient named John Moore had his cancerous spleen removed under surgery at the University of California. Without his knowledge or consent some of the cells from his spleen were cultured and found to produce a protein which could be used in the manufacture of anti-cancer drugs. The estimated value of this cell-line to the pharmaceutical industry is $3 billion. In 1984 the California Supreme Court ruled that he was not entitled to any of these profits.

A US company called Biocyte holds a patent on (owns) all umbilical cord cells. Systemix Inc has a patent on (owns) all human bone marrow stem cells, these being the progenitors of all cells in the blood. The worldwide market for cell lines and tissue cultures was estimated to be worth $426.7 million to the corporations in 1996. Not only cells but also fragments of DNA can be patented (owned) in this way. Incyte, for example, has applied for patents on 1.2 million fragments of human DNA. The logic of this is that ‘genes for’ particular diseases such as cystic fibrosis, diabetes, various cancers etc could become the property of pharmaceutical companies who could then make huge profits on tests for such genes and genebased therapies. There is no space here to get into a lengthy criticism of the reductionist idea that individual genes simply map onto well-defined physical traits underlying the whole theory and practice of GM. It’s enough to say that research into patenting (owning), for example, a supposed’ breast cancer gene’ is of little benefit to humanity if it is true, as some scientists have estimated, that 90% of breast cancers are unrelated to genetics but are triggered by environmental pollution, diet and lifestyle factors. So what’s new? Capitalism, indeed class-society in general, always seizes the living and turns it into profit and power, declares ownership where previously there was only life: from the enclosure of the commons to the seizing of millions of human beings from Africa to be slaves to the current looting of tropical biodiversity for use in the biotech labs.

[biotech-news-feed]

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its diversification plans. #BioTech #science

[leprivatebanker]

Incyte earnings beat by $0.04, revenue topped estimates

[djchorlocontrolection]

Entity - Heart Attack (Scratches Johnny One Move & Vocals MC Incyte) 2006

[columbianewsupdates]

Pancreatic Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison

http://dlvr.it/TDwH45

[thealphareporter]

Pancreatic Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison

http://dlvr.it/TDwFkQ

[hopetribune]

Pancreatic Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison

http://dlvr.it/TDw7yQ

[pier-carlo-universe]

Torino: Arriva la "Vitiligine Week" in Campania e in tutta Italia, incontri gratuiti con i dermatologi per i pazienti

Dal 25 al 30 novembre, un’iniziativa nazionale promossa da SIDeMaST per sensibilizzare sulla vitiligine e offrire supporto specialistico gratuito.

Dal 25 al 30 novembre, un’iniziativa nazionale promossa da SIDeMaST per sensibilizzare sulla vitiligine e offrire supporto specialistico gratuito. Articolo Completo: Dal 25 al 30 novembre, l’Italia ospiterà la Vitiligine Week, una settimana dedicata a chi convive con la vitiligine, una malattia autoimmune che colpisce la pigmentazione della pelle. La campagna, organizzata dalla Società Italiana…

[conversationpoint]

Pancreatic Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison

http://dlvr.it/TDw7Sy

[universalnewspoint]

Pancreatic Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison

http://dlvr.it/TDw7Hr

[newsheadlinesnow]

Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, MOA, ROA by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Incyte Crp

http://dlvr.it/TDgHTn

[colinwilson11]

Merkel Cell Carcinoma Market To Grow At Highest Pace Owing To Rising Incidence Of Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare form of skin cancer that forms in the skin cells known as Merkel cells or touch receptors. It often appears as a solitary red, purple, or skin-colored nodule on sun-exposed areas such as the head and neck regions. MCC grows and spreads rapidly causing swelling of nearby lymph nodes. Merkel cell carcinoma treatment includes radiation therapy, chemotherapy, and surgery. Depending on the stage of the cancer, treatment options may involve a combination of these therapies.

The Merkel Cell Carcinoma Market  is estimated to be valued at US$ 2.51 Bn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the Merkel Cell Carcinoma Market are Merck, Incyte Corporation, Kartos Therapeutics, Inc., Bristol-Myers Squibb, and Amgen Inc. Merck and Incyte Corporation are leading pharmaceutical companies offering immunotherapies for Merkel cell carcinoma treatment.

Rising incidence of Merkel cell carcinoma worldwide is a key factor driving the market growth. According to studies, MCC incidence rates have tripled over the past 20 years. Increasing exposure to ultraviolet radiation from sun exposure is contributing to the rising caseload of MCC.

Ongoing research and development activities for developing effective treatment options is fueling market growth. Pharmaceutical companies are engaged in developing monoclonal antibody therapies, immune checkpoint inhibitors, and combination therapies to improve treatment outcomes in Merkel cell carcinoma.

Market Trends

Growing preference for targeted therapy - Introduction of immune checkpoint inhibitors and targeted monoclonal antibody therapies is revolutionizing Merkel cell carcinoma treatment. Drugs like avelumab and pembrolizumab offer more efficacious treatment with fewer side effects compared to chemotherapy.

Rising focus on combination therapies - Combination of chemotherapy with immunotherapy is emerging as a promising treatment approach. Ongoing clinical trials are evaluating efficacy of combining chemotherapies like cisplatin with immune checkpoint inhibitors. Such combination regimens may achieve high response rates.

Market Opportunities

Development of novel drug candidates - Several biotech companies are working on developing novel drug candidates like anti-PD-L1 monoclonal antibodies, vaccines, and oncolytic virus therapies to treat Merkel cell carcinoma. Success of such candidates can reap high returns.

Increasing screening and early diagnosis - Initiatives to raise awareness about MCC and incorporate screening of high-risk groups can help detect MCC at early stages. This provides scope for intervening with curative therapies.

Impact Of COVID-19 On Merkel Cell Carcinoma Market Growth

The COVID-19 pandemic posed significant challenges for the Merkel cell carcinoma market. During the initial phases of the pandemic, patients avoided or delayed medical care due to fears of virus exposure or lockdowns, resulting in delayed diagnosis and treatment of Merkel cell carcinoma. This negatively impacted market growth in the short term. However, as the healthcare systems adapted to the pandemic by implementing strict safety protocols, the number of patients seeking treatment gradually increased. Though the market experienced a temporary dip, the long term impact is expected to be marginal. As the focus shifts to post-COVID recovery, efforts must be made to promote early detection and ensure uninterrupted access to care. Teleoncology can help maintain patient engagement and support. Vaccination drives must continue to alleviate pressure on hospitals and enable prioritization of cancer treatment. With prudent strategies, the market is well-positioned to get back on its pre-pandemic growth trajectory.

Geographical Regions With High Merkel Cell Carcinoma Market Valve Concentration

The United States represents the largest geographical market for Merkel cell carcinoma treatment in terms of value. This is primarily due to the high prevalence of the disease and well-developed healthcare infrastructure in the country. Within the US, states like Florida, California and Arizona have emerged as major hotspots with higher caseloads. These southern regions experience warmer and sunnier weather for most part of the year. Extensive sun exposure increases risk and has contributed to US retaining its top position. Europe is the second largest regional market led by markets like Germany, United Kingdom and France. However, the Asia Pacific region is witnessing fastest market growth driven by improving access to healthcare in India and China. Rising awareness among physicians and public regarding early detection is further propelling the APAC market.

Get more insights on this topic: https://www.ukwebwire.com/merkel-cell-carcinoma-market-poised-for-growth-due-to-advancements-in-targeted-cancer-therapies/

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

 What Are The Key Data Covered In This Merkel Cell Carcinoma Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Merkel Cell Carcinoma Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Merkel Cell Carcinoma Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Merkel Cell Carcinoma Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Merkel Cell Carcinoma Market vendors

FAQ’s

Q.1 What are the main factors influencing the Merkel Cell Carcinoma Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Merkel Cell Carcinoma Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Merkel Cell Carcinoma Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[biotech-news-feed]

Sonic Incytes Medical has announced receipt of FDA 510(k) clearance for its Velacur Determined Fat Fraction (VDFF). The post FDA grants clearance to Sonic Incytes’ VDFF for liver health assessment appeared first on Medical Device Network. #BioTech #science